Dr. James Field on Breaking the 'Cognition Barrier' in Antibody Discovery with AI and Robotics
We're fortunate to speak with Dr. James Field, founder and CEO of LabGenius, a leading machine learning (ML)-driven protein engineering company headquartered in London. This pioneering startup is using artificial intelligence (AI) and robotics to accelerate the discovery of next-generation therapeutic antibodies for the treatment of diseases like cancer. With traditional methods proving slow and unreliable, LabGenius offers a novel approach that could revolutionize the way we discover and develop treatments.
Topics: AI & Digital